Real-world outcomes of mosunetuzumab use in relapsed/refractory indolent lymphomas: a CUBIC consortium analysis

Blood Neoplasia · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles